| Literature DB >> 29202775 |
My-Nuong Thi Nguyen1, Thuy-Duong Ho-Huynh2.
Abstract
BACKGROUND: The holistic approach of traditional medicine renders the identification of its mechanisms of action difficult. Microarray technology provides an efficient way to analyze the complex genome-wide gene expression of cells treated with mixtures of medicinal ingredients. We performed transcriptional profiling of MCF-7 cells treated with Nam Dia Long (NDL), a Vietnamese traditional formula, to explore the mechanism of action underlying the apoptosis inducing effect of this formula reported in a previous study.Entities:
Keywords: Apoptosis; Breast cancer; Microarray profiling; Nam Dia long; Traditional medicine
Mesh:
Substances:
Year: 2017 PMID: 29202775 PMCID: PMC5716261 DOI: 10.1186/s12906-017-2027-2
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
Top 10 differentially expressed genes at 24 h and 48 h treatment
| Upregulation | Downregulation | ||||||
|---|---|---|---|---|---|---|---|
| 24 h | 48 h | 24 h | 48 h | ||||
| Gene | Fold change | Gene | Fold change | Gene | Fold change | Gene | Fold change |
| AKR1C4 | 11.81 ± 0.28 | FAM129A | 18.46 ± 0.25 | TXNIP | −4.17 ± 0.65 | TXNIP | −12.75 ± 0.43 |
| AKR1C3 | 9.15 ± 0.18 | GDF15 | 15.70 ± 0.27 | GPER | −3.10 ± 0.25 | AFAP1L2 | −5.26 ± 0.32 |
| AKR1C2 | 7.44 ± 0.21 | DDIT3 | 14.73 ± 0.32 | KCNK12 | −2.79 ± 0.78 | ID3 | −4.52 ± 0.38 |
| FGB | 5.72 ± 0.73 | FLJ35767 | 14.48 ± 0.22 | AFAP1L2 | −2.56 ± 0.34 | EFEMP1 | −4.27 ± 0.38 |
| CYP1A1 | 5.30 ± 0.22 | HSPA6 | 14.23 ± 0.49 | SAMD11 | −2.45 ± 0.24 | NUDT1 | −4.21 ± 0.18 |
| GDF15 | 4.50 ± 0.20 | LCN2 | 12.99 ± 0.27 | KCNJ8 | −2.39 ± 0.23 | ID1 | −4.05 ± 0.51 |
| FGG | 4.43 ± 0.48 | AKR1C3 | 12.88 ± 0.31 | EFEMP1 | −2.29 ± 0.29 | CCL2 | −4.02 ± 0.38 |
| ADM | 4.18 ± 0.50 | AKR1C4 | 11.33 ± 0.30 | ID1 | −2.12 ± 0.75 | GPER | −3.99 ± 0.20 |
| RASD1 | 4.15 ± 0.78 | CYP1A1 | 11.27 ± 0.23 | SMAD7 | −2.02 ± 0.13 | ELOVL2 | −3.91 ± 0.19 |
| ABCC3 | 4.11 ± 0.44 | F7 | 10.84 ± 0.20 | ID3 | −2.00 ± 0.50 | KCNJ8 | −3.88 ± 0.19 |
Each value represents mean ± SD (n = 3)
Top differentially expressed genes at both time points
| Symbol | Name | Fold change | |
|---|---|---|---|
| 24 h | 48 h | ||
| Upregulated at 24 h and 48 h | |||
| FAM129A | Family with sequence similarity 129 member A | 1.80 ± 0.26 | 18.46 ± 0.25 |
| GDF15 | Growth differentiation factor 15 | 4.50 ± 0.20 | 15.70 ± 0.27 |
| DDIT3 | DNA damage inducible transcript 3 | 2.39 ± 0.66 | 14.73 ± 0.32 |
| FLJ35767 | 2.30 ± 0.42 | 14.48 ± 0.22 | |
| HSPA6 | Heat shock protein family A (Hsp70) member 6 | 3.49 ± 0.28 | 14.23 ± 0.49 |
| LCN2 | Lipocalin 2 | 1.54 ± 0.40 | 12.99 ± 0.27 |
| AKR1C3 | Aldo-keto reductase family 1 member C3 | 9.15 ± 0.18 | 12.88 ± 0.31 |
| AKR1C4 | Aldo-keto reductase family 1 member C4 | 11.81 ± 0.28 | 11.33 ± 0.30 |
| CYP1A1 | Cytochrome P450 family 1 subfamily A member 1 | 5.30 ± 0.22 | 11.27 ± 0.23 |
| F7 | Coagulation factor VII | 1.65 ± 0.10 | 10.84 ± 0.20 |
| Down-regulated at 24 h and 48 h | |||
| TXNIP | Thioredoxin-interacting protein | −4.17 ± 0.65 | −12.75 ± 0.43 |
| AFAP1L2 | Actin filament associated protein 1 like 2 | −2.56 ± 0.34 | −5.26 ± 0.32 |
| ID3 | Inhibitor of DNA binding 3 | −2.00 ± 0.50 | −4.52 ± 0.38 |
| EFEMP1 | EGF containing fibulin like extracellular matrix protein 1 | −2.29 ± 0.29 | −4.27 ± 0.38 |
| NUDT1 | Nudix hydrolase 1 | −1.52 ± 0.08 | −4.21 ± 0.18 |
| ID1 | Inhibitor of DNA binding 1 | −2.12 ± 0.75 | −4.05 ± 0.51 |
| KCNJ8 | Potassium voltage-gated channel subfamily J member 8 | −2.39 ± 0.23 | −3.88 ± 0.19 |
| GPER | The G-protein-coupled estrogen receptor-1 | −3.10 ± 0.25 | −3.41 ± 0.17 |
| ID2 | Inhibitor of DNA binding 2 | −1.84 ± 0.23 | −3.13 ± 0.20 |
| Up-regulated at 24 h, down-regulated at 48 h | |||
| ANGPTL4 | Angiopoietin-like 4 | 2.74 ± 0.40 | −2.72 ± 0.35 |
| IL8 | Interleukin-8 | 2.72 ± 0.61 | −2.56 ± 0.36 |
| ADM | Adrenomedullin | 4.18 ± 0.50 | −1.84 ± 0.61 |
Each value represents mean ± SD (n = 3)
Fig. 1Top IPA canonical pathways identified at 24 h and 48 h after NDL treatment of MCF-7 cells (p ≤ 0.001)
Top URs predicted by the IPA at 24 h and 48 h after NDL treatment of MCF-7 cells
| Upstream Regulator | Molecule Type |
| z-score | Upstream Regulator | Molecule Type |
| z-score |
|---|---|---|---|---|---|---|---|
| 24 h | 48 h | ||||||
| Activated | |||||||
| Doxorubicin | chemical drug | 1.2E-16 | 3.32 | TP53 | transcription regulator | 9.8E-50 | 5.38 |
| Cigarette smoke | chemical toxicant | 2.8E-15 | 2.07 | CDKN1A | kinase | 1.3E-48 | 4.11 |
| TNF | cytokine | 1.6E-13 | 2.27 | NUPR1 | transcription regulator | 1.6E-32 | 6.43 |
| Hydrogen peroxide | chemical - endogenous mammalian | 1.9E-11 | 2.07 | Calcitriol | chemical drug | 1.6E-30 | 4.73 |
| NFE2L2 | transcription regulator | 1.0E-10 | 2.68 | Doxorubicin | chemical drug | 6.1E-23 | 3.33 |
| Inhibited | |||||||
| SFTPA1 | transporter | 4.5E-09 | −2.45 | RABL6 | other | 1.9E-38 | −5.40 |
| Actinomycin D | chemical drug | 4.6E-09 | −2.13 | ERBB2 | kinase | 1.0E-29 | −2.37 |
| N-acetyl-L-cysteine | chemical drug | 1.8E-06 | −2.36 | E2F1 | transcription regulator | 5.4E-28 | −3.41 |
| SB203580 | chemical - kinase inhibitor | 3.5E-06 | −2.37 | Beta-estradiol | chemical - endogenous mammalian | 7.7E-28 | −2.02 |
| CSF2 | cytokine | 2.0E-27 | −5.58 | ||||
Fold changes in expression of 5 genes obtained from qRT-PCR and microarray data
| Gene | Microarray | qRT-PCR | ||||
|---|---|---|---|---|---|---|
| 24 h | 48 h | 24 h/48 h ratio | 24 h | 48 h | 24 h/48 h ratio | |
| ERN1 | 1.19 ± 0.10 | 2.26 ± 0.23 | 1.9 | 1.68 ± 0.32 | 2.10 ± 0.53 | 1.25 |
| GADD45A | 1.60 ± 0.10 | 3.84 ± 0.07 | 2.4 | 2.84 ± 1.17 | 6.15 ± 3.43 | 2.2 |
| CDKN1A | −1.22 ± 0.22 | 2.35 ± 0.12 | 2 | −0.95 ± 1.98 | 2.91 ± 0.69 | 3 |
| HMOX1 | 3.97 ± 0.17 | 10.05 ± 0.30 | 2.5 | 5.69 ± 0.90 | 17.40 ± 7.54 | 3 |
| ESR1 | −1.33 ± 0.12 | −2.14 ± 0.11 | 1.6 | −1.23 ± 0.09 | −1.66 ± 0.87 | 1.3 |
Each value represents mean ± SD (n = 3)
Fig. 2Real-time RT-PCR analysis of gene expression level after treating MCF-7 cells with NDL for 24, 36 and 48 h. Fold change indicated relative quantitation normalized to GADPH. Fold change >1 and <1 indicated upregulation and downregulation, respectively. The statistical differences between the treatment and control conditions were analyzed by two-tailed paired Student’s t-tests (*p < 0.05; **p < 0.01; ***p < 0.001). a, ER and oxidative stress related genes; b, cell cyle and apoptosis related genes
Fig. 3Western blot analysis of some differentially expressed genes in NDL treated MCF-7 cells
Real-time RT-PCR analysis of gene expression level after treating MCF-7 cells with NDL for 24, 36 and 48 h
| Gene | Realtime RT-PCR | ||
|---|---|---|---|
| 24 h | 36 h | 48 h | |
| ER stress | |||
| GRP78 | 1.02 ± 0.16 | 10.82 ± 3.05** | 10.06 ± 3.05** |
| ERN1 | 1.68 ± 0.32 | 8.86 ± 6.54* | 2.10 ± 0.53* |
| ATF4 | 1.75 ± 0.37* | 3.67 ± 0.61** | 1.11 ± 0.24 |
| XBP1 | 2.71 ± 1.84 | 2.17 ± 0.06** | 0.60 ± 0.24 |
| DDIT3 | 0.94 ± 0.59 | 26.45 ± 14.47* | 4.56 ± 1.57* |
| FAM129A | 4.52 ± 1.84* | 44.20 ± 11.70** | 34.84 ± 9.14** |
| GDF15 | 5.65 ± 0.72** | 35.36 ± 9.23* | 19.49 ± 7.78** |
| p53 pathway | |||
| TP53 | 2.06 ± 0.95 | 2.46 ± 0.05*** | 1.30 ± 0.23 |
| RELA | 0.90 ± 0.32 | 1.65 ± 0.26* | 1.14 ± 0.41 |
| GADD45A | 2.84 ± 1.17 | 12.82 ± 3.45** | 6.15 ± 3.43* |
| CDKN1A | 0.76 ± 0.46 | 3.26 ± 0.17*** | 2.91 ± 0.69* |
| Cell cycle | |||
| CDK1 | 0.88 ± 0.12 | 0.61 ± 0.07* | 0.41 ± 0.08* |
| CDK2 | 0.75 ± 0.29 | 0.64 ± 0.08* | 0.37 ± 0.18 |
| CCNB | 0.95 ± 0.33 | 0.71 ± 0.38 | 0.19 ± 0.12* |
| CCNE | 0.70 ± 0.32 | 1.01 ± 0.26 | 0.48 ± 0.13* |
| CCNA2 | 0.66 ± 0.33 | 0.81 ± 0.17 | 0.50 ± 0.24* |
| Apoptosis | |||
| BCL2 | 0.37 ± 0.12* | 0.48 ± 0.21 | 0.25 ± 0.11* |
| BAX | 0.70 ± 0.23 | 1.02 ± 0.17 | 3.28 ± 1.03* |
| CAS9 | 1.30 ± 0.17 | 1.99 ± 0.87 | 2.23 ± 0.44* |
| CAS8 | 0.96 ± 0.21 | 2.52 ± 0.62* | 2.30 ± 0.14* |
| NOXA | 1.29 ± 0.59 | 4.43 ± 1.75* | 0.57 ± 0.40 |
| PUMA | 3.31 ± 3.10 | 6.76 ± 1.75** | 11.95 ± 5.74* |
| TRAIL | 2.44 ± 1.87 | 2.44 ± 1.82 | 1.78 ± 0.03*** |
| Oxidative stress response | |||
| NFE2L2 | 0.91 ± 0.51 | 1.53 ± 0.13* | 1.05 ± 0.61 |
| HMOX1 | 5.69 ± 0.90** | 9.37 ± 3.96* | 17.40 ± 7.54* |
| CAT | 1.41 ± 0.33 | 1.56 ± 0.31 | 0.64 ± 0.31 |
| SOD1 | 1.59 ± 0.43 | 2.44 ± 0.95 | 0.50 ± 0.23 |
| SOD2 | 1.10 ± 0.37 | 1.30 ± 0.21 | 0.85 ± 0.05* |
| GPX-1 | 1.87 ± 0.31* | 3.83 ± 2.50 | 0.80 ± 0.57 |
| Estrogen receptor | |||
| ESR1 | 0.81 ± 0.06* | 0.73 ± 0.11 | 0.70 ± 0.29 |
| ESR2 | 2.08 ± 1.20 | 2.70 ± 0.61* | 2.03 ± 0.58 |
Each value represents mean ± SD (n = 3). Fold change indicated relative quantitation compared to GADPH. Fold change >1 indicates upregulation while fold change < 1 indicates down regulation. The statistical differences between the treatment and control were analyzed by two-tailed paired Student’s t-tests (*p < 0.05; **p < 0.01; ***p < 0.001)